FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 816 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour April 4, 2025 Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials June 29, 2020 High Jumper Training for Her Fifth Olympics Uses Personal Breast Cancer... December 9, 2020 In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in... March 10, 2026 Load more HOT NEWS FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... ESMO Publishes First Guidance on the Safe Use of Large Language... Withdrawal of the Application to Change the EMA Marketing Authorisation for... Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for...
